Tricyclic GyrB/ParE (TriBE) Inhibitors: A New Class of Broad-Spectrum Dual-Targeting Antibacterial Agents

Leslie W. Tari(Arcturus Therapeutics (United States)), John Finn(Arcturus Therapeutics (United States)), Junhu Zhang(Jilin University), Vickie Brown‐Driver(Arcturus Therapeutics (United States)), Michael Trzoss(Arcturus Therapeutics (United States)), Jeff B. Locke(Arcturus Therapeutics (United States)), Thanh Lam(Arcturus Therapeutics (United States)), Dean L. Shinabarger(Michigan United), Grayson Hough(Arcturus Therapeutics (United States)), Suk Joong Lee(Arcturus Therapeutics (United States)), Jay C. Nix(Lawrence Berkeley National Laboratory), Bryan P. Kwan(Arcturus Therapeutics (United States)), Amanda Castellano(Arcturus Therapeutics (United States)), Doug Phillipson(Arcturus Therapeutics (United States)), Daniel C. Bensen(State Street (United States)), S. Akers-Rodriguez(Arcturus Therapeutics (United States)), Karen Joy Shaw(Arcturus Therapeutics (United States)), Voon Ong(Arcturus Therapeutics (United States)), Xiaoming Li(Qiqihar Medical University), Zhiyong Chen(Hunan University), Timothy M. Murphy, Toan B. Nguyen(Lawrence Livermore National Laboratory), Chris M. Pillar(Michigan United), Mark L. Cunningham(Arcturus Therapeutics (United States)), Felice C. Lightstone, Sergio Wong(Lawrence Livermore National Laboratory), Kirk Nelson(Arcturus Therapeutics (United States))
PLoS ONE
December 26, 2013
Cited by 104


Related Papers